David McWilliams

David B. McWilliams is currently Chairman at BioHouston, Inc. and Greenwich LifeSciences, Inc. (since 2016), Director at Texas Healthcare & Bioscience Institute and Norwell Mfg.
Co., Inc., and Member of The Phi Beta Kappa Society.
Former roles include President, Chief Executive Officer & Director at Encysive Pharmaceuticals, Inc. (1992–2002); Chief Executive Officer & Director at Signase, Inc.; President & Chief Executive Officer at Bacterial Barcodes, Inc. (2003); President & Chief Executive Officer at Opexa Therapeutics, Inc. (2006–2008); President & Chief Executive Officer at Kallestad Diagnostics, Inc.; Director at Repros Therapeutics, Inc.; Director at Novelos Therapeutics, Inc. (2005–2011); Director at Technology & Entrepreneurship Center of Houston; Director at ApoCell, Inc.; General Manager at Abbott Laboratories; Management Consultant at McKinsey & Co., Inc.; and President-Harleco Diagnostics Division at EM Industries LLC.
Education includes an MBA from The University of Chicago and undergraduate studies at Washington & Jefferson College.